Advanced Accelerator Applications - AAA

GiPharma acquires a new licence in France

Gipharma was recently granted marketing authorization in France for Mibitec, a generic version of the widest used SPECT cardiac imaging agent. Mibitec has approved indications for Myocardial perfusion scintigraphy, detection and localization of coronary artery disease and myocardial infarction, assessment of global ventricular function, detection of suspected breast cancer, and localization of hyper-functioning parathyroid tissue.

AAA to support University of Lausanne Hospitals

The University of Lausanne Hospitals (CHUV) will participate in a study on the impact of F-18 Fluorocholine PET/CT and MR Imaging/Spectroscopy in the Management of primary and recurrent prostate cancer. The sponsors and collaborators of this study are AAA and the Centre d’Imagerie Biomédicale (CIBM) in Lausanne. This study will run in parallel to the work-up of primary prostate cancer, as the F-Choline radiopharmaceutical will be available during the time of study at absolutely no cost to patients or CHUV. A number of studies have demonstrated the benefits of F-18 FCH PET/CT for these patients and this indication is currently not reimbursed by the Swiss obligatory health insurance providers.